THIS IS WHAT YOU NEED TO KNOW BEFORE CONSIDERING TO BUY ELTP
The stock is massively over priced
The FDA has already REJECTED Sequest with no chance for approval in time to be meaningful in the slightest, if ever.
The CEO has STOPPED offering live Q&A to his shareholders curiously ever since Sequest was REJECTED
The CEO insists upon presubmitted, prescreened questions to be forwarded in advance of shareholder calls so they may be hand chosen as to which to answer
Sales of Elites generics have SLIPPED as compared to its previous quarter and the year ago quarter
Dilution of shareholders continues to EXPLODE with little to show for it except a rejected NDA and a partnership with BP, I mean, a startup
Although the share price remains wildly over priced, it has been in a continuous decline for good reason. Once a 97 cent high flyer and as early as this past July at 39 cents, currently at a depressing 14
A PR stating Sequest BE is under serious scrutiny and question as many have learned the absence of Tmax data in the announced results of which Sequest was ultimately REJECTED by the FDA
Elite moving forward with the filing of Sequests NDA with the knowledge a similar IR ADF Avridi had already been overwhelmingly rejected by the FDAs AdCom for extended Tmax delay!!
Contrary to popular BS, the FDA has stated one of its reasons it REJECTED Sequest was due to SAFETY ISSUES, not labeling
Elite continues to be admonished by the FDA, first via OBSERVATION and subsequently being slapped with a WARNING LETTER for inadequately monitoring and handling of adverse drug experiences. OUTRAGEOUS!!
